Hubro Therapeutics AACR 2022 abstract published

As previously announced, the abstract “Detection of TGFbR2 frameshift mutation” is now available online at The abstract describes an early occurring cancer driver mutation which is a potential biomarker for early detection of cancer (E.G. Lynch Syndrome) as well as for monitoring response to cancer treatment.

Poster: Detection of TGFbR2 a10→a9 frameshift mutation in cell free DNA of liquid biopsies from MSI-colorectal cancer patients.

The poster is scheduled for presentation during the ACCR congress 8-13 April 2022.

Session Title:                      Cell-Free DNA 1
Session Start Time:            4/12/2022 1:30:00 PM
Session End Time:             4/12/2022 5:00:00 PM
Location:                             Poster Section 30

This website uses cookies to ensure you get the best experience on our website.